Microsure has announced the successful closing of its Series B2 investment round securing € 38 million in development capital. With this funding, Microsure will finalise development of its newest microsurgical robot MUSA-3 for clinical studies followed by FDA clearance in the US and CE-mark in Europe.
Microsure's microsurgical robot MUSA-3 has been designed with the aim of revolutionising the field of open microsurgery. Building on the success of MUSA-2, MUSA-3 offers enhanced dexterity and a wide workspace, tremor reduction for enhanced precision and seamless integration with surgeons' existing preferred micro-instruments of different well-known top brands. Its adaptability allows it to be used in a wide range of surgical procedures. MUSA-3 combines surgeon comfort with improved ergonomics, enabling surgeons to work from a surgeon console with digital exoscopes or hybrid surgical microscopes.
The financing round welcomes a host of new investors, including the European Innovation Council Fund (EICF), kineo, Invest-NL, and several prominent private investor groups. Microsure also acknowledges the unwavering support of key existing shareholders including deep-tech venture capital firm Innovation Industries, BOM Ventures, private investors Ten Cate Investerings Maatschappij (TCIM), Venturing Tech, Eindhoven University of Technology (TU/e), and Microsure Founders.
Microsure's commitment to innovation has also been recognised with an EIC Accelerator grant, and an Innovation Loan from RvO, a division of the Dutch Ministry of Economic Affairs. Additionally, the company has entered into an asset financing agreement with kineo, enabling Microsure to offer leasing options to hospitals adopting MUSA-3.
Several clinical studies have been undertaken with a clinical prototype, MUSA-2. These studies, performed at Maastricht University Medical Center in the Netherlands and Uppsala Academic Hospital in Sweden include around 50 patients to date and encompass a wide spectrum of surgical indications, yielding promising results and invaluable insights for the development of MUSA-3. In addition, an in-vitro study in Uppsala featuring 20 microsurgeons performing over 200 anastomoses reveals a remarkably swift learning curve using MUSA.
